The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
D | Dermatologicals | |
2
|
D11 | Other dermatological preparations | |
3
|
D11A | Other dermatological preparations | |
4
|
D11AH | Agents for dermatitis, excluding corticosteroids | |
5
|
D11AH12 |
| Active Ingredient |
|---|
|
Nemolizumab is a humanised IgG2 monoclonal antibody that inhibits interleukin-31 (IL-31) signalling by binding selectively to interleukin-31 receptor alpha (IL-31 RA). IL-31 is a naturally occurring cytokine that is involved in pruritus, inflammation, epidermal dysregulation, and fibrosis. Nemolizumab inhibited IL-31-induced responses including the release of proinflammatory cytokines and chemokines. |
| Document | Type | Information Source | |
|---|---|---|---|
| NEMLUVIO Powder and solvent for solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) |